PYC pyc therapeutics limited

Forecasts and valuationMaintain BUY and $2.40 price target. We...

  1. 2,526 Posts.
    lightbulb Created with Sketch. 1654
    Forecasts and valuation

    Maintain BUY and $2.40 price target. We continue to like the risk/reward asymmetry associated with the stock, now without a funding overhang and multiple key de-risking value inflection points.

    Recall, we reach our $2.40 price target on a risked basis, and assume a 25% probability of success (PoS) in RP11, 15% in ADOA, 10% in ADPKD (autosomal dominant polycystic kidney disease) and 5% in Phelan McDermid. On a fully de-risked basis, we see potential upside to $12/share.

    Elyse Shapiro | Analyst | Canaccord Genuity (Australia) Ltd. | [email protected] | +61.3.8688.9136 Madeleine Williams | Analyst | Canaccord Genuity (Australia) Ltd. | [email protected] | +61.3.8688.9102
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.33
Change
0.080(6.43%)
Mkt cap ! $772.8M
Open High Low Value Volume
$1.27 $1.35 $1.21 $763.8K 595.4K

Buyers (Bids)

No. Vol. Price($)
2 97719 $1.30
 

Sellers (Offers)

Price($) Vol. No.
$1.33 6599 1
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.